Compare Becton Dickinson and Co (BDX) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Microsoft — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Microsoft trades at $501.98 (market cap $3.76T). The key difference: Microsoft is far larger — about 76.8× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | MSFT | |
|---|---|---|
Market Cap | $48.93B | $3.76T |
Sector | Health | Technology |
52-Week High | $185.39 | $542.07 |
52-Week Low | $138.62 | $352.83 |
Enterprise Value | $65.03B | $3.74T |
Dividend Yield | 2.34% | 0.72% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Microsoft (MSFT) trades at $503.81, up 0.76% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 estimate. Revenue growth is steady, reaching $281.72B in 2025, supported by a net income margin of 40.31%. Analyst consensus is overwhelmingly positive, with 80.49% buy ratings and a $553.70 price target. Recent news highlights AI leadership and Azure momentum, though concerns over capital expenditures persist.
Outlook remains favorable with AI-driven growth and cloud expansion, but risks include high valuation (P/E 28.19) and competitive pressures. Investment opportunity lies in sustained earnings momentum and dividend stability, while volatility from tech sector shifts and macroeconomic factors warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
